Source comparison
Sermorelin Perimenopause Research Mechanism: Comparison of Hormonal Interventions
Before committing to a research protocol, understanding how sermorelin compares to alternative hormonal interventions clarifies which mechanism best addresses specific perimenopausal deficits. The table below contrasts sermorelin against estrogen HRT, exogenou
This comparison does not assign a generated winner or score.
- Before committing to a research protocol, understanding how sermorelin compares to alternative hormonal interventions clarifies which mechanism best addresses specific perimenopausal deficits. The table below contrasts sermorelin against estrogen HRT, exogenous rhGH, and non-intervention controls across five key research parameters.
- Sermorelin (200–300 mcg nightly)
- GHRH receptor agonism → endogenous GH pulsatile release
- +22–35% from baseline
- Yes. Somatostatin feedback intact
- Favorable. No supraphysiologic GH exposure, minimal insulin resistance risk
- Optimal for restoring GH axis function without overriding negative feedback; first-line choice for perimenopause GH research
- Estrogen-only HRT (transdermal 0.05 mg/day)
- ER-alpha/beta agonism → hypothalamic thermoregulation, bone ER signaling
- +5–8% (indirect via GHRH stimulation)
- Partial. Estrogen enhances GHRH but does not restore pituitary responsiveness
- Well-established. Thrombosis risk in oral formulations, breast tissue proliferation concern
- Addresses vasomotor symptoms and bone loss but leaves GH axis decline untreated; does not restore anabolic signaling
- Recombinant hGH (0.2–0.4 mg/day subcutaneous)
- Direct GH receptor activation (continuous supraphysiologic exposure)
- +80–150% (pharmacologic, not physiologic)
- No. Continuous exposure suppresses endogenous pulsatility via negative feedback
- Risk of insulin resistance, joint effusion, carpal tunnel syndrome at sustained doses
- Effective for severe GH deficiency but physiologically inappropriate for perimenopause. Bypasses natural regulatory mechanisms
- No intervention (control)
- Endogenous decline continues
- −8–12% per decade after age 40
- Progressively lost. Amplitude and frequency both decline
- No intervention risk but accelerated sarcopenia, visceral adiposity, and bone loss
- Acceptable only if GH axis decline is asymptomatic; most perimenopausal women show metabolic detriment